Daily low-dose interleukin-2 administration in steroid-refractory chronic graft-versus-host disease is feasible, safe, and efficacious; with preferential regulatory T-cell expansion
BONE MARROW TRANSPLANTATION(2010)
AI 理解论文
溯源树
样例
![](https://originalfileserver.aminer.cn/sys/aminer/pubs/mrt_preview.jpeg)
生成溯源树,研究论文发展脉络
Chat Paper
正在生成论文摘要